Erratum: STD NMR spectroscopy and molecular modelling investigation of the binding of N-acetylneuraminic acid derivatives to rhesus rotavirus VP* core (Glycobiology (2007) vol. 17 (1) (68-81) 10.1093/glycob/cwl051);STD NMR spectroscopy and molecular modeling investigation of the binding of N-acetylneuraminic acid derivatives to rhesus rotavirus VP8* core

Glycobiology

Volumn 17, Issue 1, 2007, Pages 68-81

  Haselhorst, Thomas ^a   Blanchard, Helen ^a   Frank, Martin ^a   Kraschnefski, Mark J ^a   Kiefel, Milton J ^a   Szyczew, Alex J ^a   Dyason, Jeffery C ^a   Fleming, Fiona ^b   Holloway, Gavan ^b   Coulson, Barbara S ^b   Von Itzstein, Mark ^a  

^a GRIFFITH UNIVERSITY   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

2 DEOXY 2,3 DIDEHYDRO DEXTRO N ACETYLNEURAMINIC ACID; ANTIVIRUS AGENT; DISACCHARIDE; GALACTOSE; METHYL 9 O ACETYL ALPHA DEXTRO N ACETYLNEURAMINIDE; METHYL ALPHA DEXTRO N ACETYLNEURAMINIDE; METHYL S (ALPHA DEXTRO N ACETYLNEURAMINOSYL)(2-6) 6 THIO BETA DEXTRO GALACTOPYRANOSIDE; N ACETYLNEURAMINIC ACID DERIVATIVE; PROTEIN VP8; SIALIC ACID; VIRUS PROTEIN;

ANTIVIRAL ACTIVITY; ARTICLE; BINDING SITE; COMPLEX FORMATION; CONTROLLED STUDY; DRUG PROTEIN BINDING; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; HUMAN CELL; MOLECULAR DYNAMICS; MOLECULAR MODEL; MOLECULAR RECOGNITION; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN CARBOHYDRATE INTERACTION; PROTEIN DOMAIN; ROTAVIRUS; VIRUS INFECTIVITY; VIRUS INHIBITION;

RHESUS ROTAVIRUS; ROTAVIRUS; SIA;

EID: 33845568286     PISSN: 09596658     EISSN: 14602423     Source Type: Journal    
DOI: 10.1093/glycob/cwm091     Document Type: Erratum

References (42)

1. Arias CF, Isa P, Guerrero CA, Mendez E, Zarate S, Lopez T, Espinosa R, Romero P, Lopez S. 2002. Molecular biology of rotavirus cell entry. Arch Med Res. 33:356-361.
2. Beisner B, Kool D, Marich A, Holmes IH. 1998. Characterisation of G serotype dependent non-antibody inhibitors of rotavirus in normal mouse serum. Arch Virol. 143:1277-1294.
3. Case DA, Darden TA, Cheatham TE III, Simmerling CL, Wang J, Duke RE, Luo R, Merz KM, Wang B, Pearlman DA, et al. 2004. 8th ed. San Francisco (CA): University of California.
4. Ciarlet M, Crawford SE, Cheng E, Blutt SE, Rice DA, Bergelson JM, Estes MK. 2002. Initial interaction of rotavirus strains with N-acetylneuraminic (sialic) acid residues on the cell surface correlates with VP4 genotype, not species of origin. J Virol. 76:1109-1123.
5. Ciarlet M, Crawford SE, Estes MK. 2001. Differential infection of polarized epithelial cell lines by sialic acid-dependent and sialic acid-independent rotavirus strains. J Virol. 75:11834-11850.
6. Clark SM, Roth JR, Clark ML, Barnett BB, Spendlove RS. 1981. Trypsin enhancement of rotavirus infectivity: Mechanism of enhancement. J Virol. 39:816-822.
7. Coulson BS, Londrigan SL, Lee DJ. 1997. Rotavirus contains integrin ligand sequences and a disintegrin-like domain that are implicated in virus entry into cells. Proc Natl Acad Sci USA. 94:5389-5394.
8. Dauber-Osguthorpe P, Roberts VA, Osguthorpe DJ, Wolff J, Genest M, Hagler AT. 1988. Structure and energetics of ligand binding to proteins: Escherichia coli dihydrofolate reductase-trimethoprim, a drug-receptor system. Proteins. 4:31-47.
9. Delorme C, Brussow H, Sidoti J, Roche N, Karlsson K-A, Neeser J-R, Teneberg S. 2001. Glycosphingolipid binding specificities of rotavirus: identification of a sialic acid-binding epitope. J Virol. 75:2276-2287.
10. Dormitzer PR, Greenberg HB, Harrison SC. 2001. Proteolysis of monomeric recombinant rotavirus VP4 yields an oligomeric VP5* core. J Virol. 75: 7339-7350.
11. Dormitzer PR, Sun Z-YJ, Blixt O, Paulson JC, Wagner G, Harrison SC. 2002. Specificity and affinity of sialic acid binding by the rhesus rotavirus VP8* core. J Virol. 76:10512-10517.
12. Dormitzer PR, Sun Z-YJ, Wagner G, Harrison SC. 2002. The RRV VP4 sialic acid binding domain has a galectin fold with a novel carbohydrate binding site. EMBO J. 21:885-897.
13. Estes MK. 2001. In: Knipe DM, Howley PM, editors. Fields Virology. 4th ed. Philadelphia (PA): Lippincott-Raven Publishers.
14. Fischer TK, Breese JS, Glass RI. 2004. Rotavirus vaccines and the prevention of hospital-acquired diarrhea in children. Vaccine. 22:S49-S54.
15. Franco MA, Greenberg HB. 2001. Challenges for rotavirus vaccines. Virology. 281:153-155.
16. Fukudome K, Yoshie O, Konno T. 1989. Comparison of human, simian, and bovine rotaviruses for requirement of sialic acid in hemagglutination and cell adsorption. Virology. 172:196-205.
17. Greenberg HB, Valdesuso J, van Wyke K, Midthun K, Walsh M, McAuliffe V, Wyatt RG, Kalica AR, Flores J, Hoshino Y. 1983. Production and preliminary characterization of monoclonal antibodies directed at two surface proteins of rhesus rotavirus. J Virol. 47:267-275.
18. Guo C-T, Nakagomi O, Mochizuki M, Ishida H, Kiso M, Ohta Y, Suzuki T, Miyamoto D, Hidari KIPJ, Suzuki Y. 1999. Ganglioside GM(1a) on the cell surface is involved in the infection by human rotavirus KUN and MO strains. J Biochem (Tokyo). 126:683-688.
19. Haselhorst T, Weimar T, Peters T. 2001. Molecular recognition of sialyl Lewis(x) and related saccharides by two lectins. J Am Chem Soc. 123: 10705-10714.
20. 1H-NMR experiments and in silico docking experiments to probe the binding of N-acetylneuraminic acid and derivatives to Vibrio cholerae sialidase. Proteins Struct Funct Bioinform. 56:346-353.
21. Hewish MJ, Takada Y, Coulson BS. 2000. Integrins alpha2beta1 and alpha4-beta1 can mediate SA11 rotavirus attachment and entry into cells. J Virol. 74:228-236.
22. Kiefel MJ, Beisner B, Bennett S, Holmes ID, von Itzstein M. 1996. Synthesis and biological evaluation of N-acetylneuraminic acid-based rotavirus inhibitors. J Med Chem. 39:1314-1320.
23. Kononov LO, Magnusson G. 1998. Synthesis of methyl and allyl α-glycosides of N-acetylneuraminic acid in the absence of added promoter. Acta Chem Scand. 52:141-144.
24. Ludert JE, Feng N, Yu JH, Broome RL, Hoshino Y, Greenberg HB. 1996. Genetic mapping indicates that VP4 is the rotavirus cell attachment protein in vitro and in vivo. J Virol. 70:487-493.
25. Mayer M, Meyer B. 1999. Characterization of ligand binding by saturation transfer difference NMR spectroscopy. Angew Chem Int Ed. 38:1784-1788.
26. Mayer M, Meyer B. 2001. Group epitope mapping by saturation transfer difference NMR to identify segments of a ligand in direct contact with a protein receptor. J Am Chem Soc. 123:6108-6117.
27. Meindl P, Tuppy H. 1969. 2-Deoxy-2,3-dehydrosialic acids: II. Competitive inhibition of Vibrio cholerae neuraminidase by 2-deoxy-2,3-dehydro-N-acylneuraminic acids. Hoppe-Seyler's Z Physiol Chem. 350:1088-1092.
28. Mendez E, Lopez S, Cuadras MA, Romero P, Arias CF. 1999. Entry of rotaviruses is a multistep process. Virology. 263:450-459.
29. Parashar UD, Bresee JS, Gentsch JR, Glass RI. 1998. Rotavirus. Emerg Infect Dis 4:561-570.
30. Parashar UD, Hummelman EG, Bresee JS, Miller MA, Glass RI. 2003. Global illness and deaths caused by rotavirus disease in children. Emerg Infect Dis 9:565-572.
31. Pearlman DA, Case DA, Caldwell JW, Ross WS, Cheatham TE, Debolt S, Ferguson D, Seibel G, Kollman P. 1995. Amber, a package of computer-programs for applying molecular mechanics, normal-mode analysis, molecular-dynamics and free-energy calculations to simulate the structural and energetic properties of molecules. Comput Phys Commun. 91:1-41.
32. Rolsma MD, Gelberg HB, Kuhlenschmidt MS. 1994. Assay for evaluation of rotavirus-cell interactions: Identification of an enterocyte ganglioside fraction that mediates group A porcine rotavirus recognition. J Virol. 68: 258-268.
33. Scott SA, Holloway G, Coulson BS, Szyczew AJ, Kiefel MJ, von Itzstein M, Blanchard H. 2005. Crystallization and preliminary X-ray diffraction analysis of the sialic acid-binding domain (VP8*) of porcine rotavirus strain CRW-8. Acta Crystallogr. F61:617-620.
34. Shaw AL, Rothnagel R, Chen D, Ramig RF, Chiu W, Prasad BV. 1993. Three-dimensional visualization of the rotavirus hemagglutinin structure. Cell. 74:693-701.
35. Svennerholm A-M, Steele D. 2004. Progress in enteric vaccine development. Clin Gastroenterol. 18:441-445.
36. Tihova M, Dryden KA, Bellamy AR, Greenberg HB, Yeager M. 2001. Localization of membrane permeabilization and receptor binding sites on the VP4 hemagglutinin of rotavirus: Implications for cell entry. J Mol Biol. 314:985-992.
37. Wang J, Wolf RM, Caldwell JW, Kollman PA, Case DA. 2004. Development and testing of a general amber force field. J Comput Chem. 25:1157-1174.
38. Wang JM, Cieplak P, Kollman PA. 2000. How well does a restrained electrostatic potential (RESP) model perform in calculating conformational energies of organic and biological molecules?. J Comput Chem. 21: 1049-1074.
39. Wen X, Yuan Y, Kuntz DA, Rose DR, Pinto BM. 2005. A Combined STD-NMR/ molecular modeling protocol for predicting the binding modes of the glycosidase inhibitors kifunensine and salacinol to golgi alpha-mannosidase II. Biochemistry. 44:6729-6737.
40. Willoughby RE, Yolken RH. 1990. SA11 rotavirus is specifically inhibited by an acetylated sialic acid. J Infect Dis. 161:116-119.
41. Yeager M, Berriman JA, Baker TS, Bellamy AR. 1994. Three-dimensional structure of the rotavirus haemagglutinin VP4 by cryo-electron microscopy and difference map analysis. EMBO J. 13:1011-1018.
42. Zarate S, Espinosa R, Romero P, Mendez E, Arias CF, Lopez S. 2000. The VP5 domain of VP4 can mediate attachment of rotaviruses to cells. J Virol. 74:593-599.